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Problem statement
In recent years, multiple criteria decision analysis
(MCDA) has emerged as a likely alternative to address
shortcomings in health technology assessment (HTA) by
offering a more holistic perspective to value assessment
and acting as an alternative priority setting tool.
Objectives
In this abstract we develop a methodological framework
and argue that MCDA needs to subscribe to robust
methodological processes related to the selection of
objectives, criteria and attributes in order to be mean-
ingful in the context of health care decision-making and
fulfil its role in value-based assessment (VBA) and as a
resource allocation tool.
Policies targeted
A methodological framework to inform the value
assessment of new medical technologies which can
help determine coverage decisions and, possibly, pri-
cing mechanisms.
Stakeholders
Primary and secondary input from a multiplicity of
institutional, academic, and other stakeholders (clini-
cians, methodologists, health economists) under the aus-
pices of the Advance-HTA project consortium.
Region covered
A generic framework that can be applied across all WHO
regions and levels.
Methods
Study design: Methodological framework development
Time period: April 2014 – April 2015
Setting: Generic framework of value assessment that can
be applied to inpatient and outpatient settings in any
country
Interventions: Methodological framework development
Results
We propose a methodological process comprising five
distinct phases (problem structuring, model building,
model assessment, model appraisal and development of
action plans), outline the stages involved in each phase and
discuss their relevance in the HTA process. Additionally,
criteria and attributes need to satisfy a set of desired prop-
erties, otherwise the process of preference elicitation can
produce spurious results. The resulting MCDA output,
which can take the form of a single universal value index,
can be informed by stakeholder participation and therefore
can be robust and reflective of stakeholder preferences.
Conclusions
Assuming the methodological process we propose is
adhered to, the application of MCDA presents two very
distinct advantages to decision-makers in the context of
HTA and VBA: first, it acts as an instrument for eliciting
preferences for a wider set of criteria leading to a more
complete assessment of value; and, second, the process of
preference elicitation is informed by direct stakeholder
participation. Both features contribute to greater rational-
ity and increased transparency in decision-making.
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